Fig. 5: SARB hybrid targets self-renewal capacity of CRC cells. | Cell Death & Disease

Fig. 5: SARB hybrid targets self-renewal capacity of CRC cells.

From: Combination of 5-fluorouracil and thymoquinone targets stem cell gene signature in colorectal cancer cells

Fig. 5

(A) Schematic overview of the protocol used for spheroid formation assay (SFA). (B) Representative immunofluorescence images of CD133 staining (red) in 3D HCT116 and HT29 cells (n ≥ 2). Hoechst staining (blue) is used to stain the nuclei. Scale bar—100 µm. Representative bright-field images of spheroids in the control group and in the treated ones with increasing concentration of SARB in HCT116 (C), HT29 (D) and 5-FU resistant cells (E). Scale bar—250 µm. Sphere number quantification in the control and SARB-treated groups. Data represent the mean ± SEM from two independent experiments (*p < 0.05; **p < 0.01; ***p < 0.001; One way-ANOVA). Western blot analysis of CD133 in (F) HCT116, (G) HT29, and (J) 5-FU-resistant cells after SARB treatment. GAPDH served as a loading control. Western Blot images are representative for at least two independent experiments

Back to article page